Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: a meta-analysis | Zendy

Tingting Tao | Zendy; Xuehua Jiang | Zendy; Yuehong Chen | Zendy; Yiran Song | Zendy

Open Access

Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: a meta-analysis

Author(s) -

Tingting Tao,

Xuehua Jiang,

Yuehong Chen,

Yiran Song

Publication year - 2016

Publication title -

international journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.278

H-Index - 89

eISSN - 1878-3511

pISSN - 1201-9712

DOI - 10.1016/j.ijid.2016.12.023

Subject(s) - medicine , ledipasvir , sofosbuvir , ribavirin , meta analysis , discontinuation , regimen , hepatitis c , randomized controlled trial , hepatitis c virus , relative risk , gastroenterology , virology , confidence interval , virus

The addition of ribavirin (RBV) to the combination treatment of Ledipasvir (LDV) and Sofosbuvir (SOF) remains controversial in the treatment of hepatitis C virus (HCV) infection. We performed a meta-analysis to assess the efficacy and safety of the LDV-SOF with and without RBV in treating HCV genotype 1 patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research